Ranolazine earns its niche precisely because it does not work like the classic antianginals. Beta blockers, calcium blockers and nitrates all act by changing heart rate or vascular tone, but ranolazine targets the late sodium current and eases ischaemia while leaving blood pressure and pulse essentially untouched; that hemodynamic neutrality is its hallmark, so calling it hypotensive is wrong. It is reserved as adjunctive therapy when first-line agents fall short rather than being a primary choice. Two real properties remain: it modestly improves glycaemic indices such as HbA1c, and it participates in CYP3A-mediated drug interactions. Filtering for the inaccurate statement leaves the hypotensive-effect claim.
\[\boxed{\text{Has hypotensive effects}}\]